Female sex and burden of depressive symptoms predict insufficient response to telemedical treatment in adult attention-deficit/hyperactivity disorder: results from a naturalistic patient cohort during the COVID-19 pandemic.
COVID-19
WHO well-being
attention-deficit/hyperactivity disorder
depression
telemedicine
Journal
Frontiers in psychiatry
ISSN: 1664-0640
Titre abrégé: Front Psychiatry
Pays: Switzerland
ID NLM: 101545006
Informations de publication
Date de publication:
2023
2023
Historique:
received:
25
03
2023
accepted:
18
09
2023
medline:
23
10
2023
pubmed:
23
10
2023
entrez:
23
10
2023
Statut:
epublish
Résumé
Attention-deficit/hyperactivity disorder (ADHD) is a chronic neuropsychiatric disorder, that typically manifests itself during childhood and persists in a majority of the affected individuals into adulthood, negatively affecting physical and mental health. Previous studies have shown detrimental effects of the COVID-19 pandemic on mental health in individuals with ADHD. Thus, telemedicine could be a useful tool for optimizing treatment-outcomes in adult ADHD by improving treatment adherence and persistence. However, data on telemedical treatment outcomes in adult patients with ADHD is scarce. We report here the sub-cohort analysis of a naturalistic cohort of adult patients (N = 254) recruited between April 2020-April 2021, comparing the effects of telemedical treatment on participants either clinically diagnosed with depression (N = 54) or ADHD (N = 67). Participants were asked to fill out the WHO-5 repetitively during >12 weeks of telemedical treatment. Furthermore scores of WHO-5, SCL-90R and BDI-II, psychopathology, psychosocial functioning, sociodemographic data, medical records and a feedback survey were analyzed for both groups and compared. Participants with ADHD were further stratified according to the development of well-being during the study period in order to identify factors associated with a satisfactory treatment outcome. Participants with depression reported a significant improvement of well-being during the course of the study, while no such effect could be seen in participants with ADHD on a group level. Despite the good outcome, participants with depression were more severely affected at baseline, with significantly worse psychopathology and a more precarious labor and financial situation. A detailed analysis of ADHD participants without clinical improvement revealed significantly higher BDI-II scores than for ADHD participants with a satisfactory outcome ( Besides screening for depressive symptoms before telemedical treatment, future research should address the specific needs of female ADHD patients as these patients may be at a particularly high risk of being overburdened with family work.
Sections du résumé
Background
UNASSIGNED
Attention-deficit/hyperactivity disorder (ADHD) is a chronic neuropsychiatric disorder, that typically manifests itself during childhood and persists in a majority of the affected individuals into adulthood, negatively affecting physical and mental health. Previous studies have shown detrimental effects of the COVID-19 pandemic on mental health in individuals with ADHD. Thus, telemedicine could be a useful tool for optimizing treatment-outcomes in adult ADHD by improving treatment adherence and persistence. However, data on telemedical treatment outcomes in adult patients with ADHD is scarce.
Methods
UNASSIGNED
We report here the sub-cohort analysis of a naturalistic cohort of adult patients (N = 254) recruited between April 2020-April 2021, comparing the effects of telemedical treatment on participants either clinically diagnosed with depression (N = 54) or ADHD (N = 67). Participants were asked to fill out the WHO-5 repetitively during >12 weeks of telemedical treatment. Furthermore scores of WHO-5, SCL-90R and BDI-II, psychopathology, psychosocial functioning, sociodemographic data, medical records and a feedback survey were analyzed for both groups and compared. Participants with ADHD were further stratified according to the development of well-being during the study period in order to identify factors associated with a satisfactory treatment outcome.
Results
UNASSIGNED
Participants with depression reported a significant improvement of well-being during the course of the study, while no such effect could be seen in participants with ADHD on a group level. Despite the good outcome, participants with depression were more severely affected at baseline, with significantly worse psychopathology and a more precarious labor and financial situation. A detailed analysis of ADHD participants without clinical improvement revealed significantly higher BDI-II scores than for ADHD participants with a satisfactory outcome (
Conclusion
UNASSIGNED
Besides screening for depressive symptoms before telemedical treatment, future research should address the specific needs of female ADHD patients as these patients may be at a particularly high risk of being overburdened with family work.
Identifiants
pubmed: 37867771
doi: 10.3389/fpsyt.2023.1193898
pmc: PMC10585110
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1193898Informations de copyright
Copyright © 2023 Praus, Proctor, Rohrmann, Benedyk, Tost, Hennig, Meyer-Lindenberg and Wahl.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Atten Disord. 2019 Dec;23(14):1736-1745
pubmed: 28992747
Front Psychiatry. 2017 Apr 07;8:45
pubmed: 28439242
Psychother Psychosom. 2015;84(3):167-76
pubmed: 25831962
Innov Clin Neurosci. 2012 May;9(5-6):10-21
pubmed: 22808445
Qual Life Res. 2019 May;28(5):1111-1118
pubmed: 30456716
J Pers Assess. 1996 Dec;67(3):588-97
pubmed: 8991972
J Atten Disord. 2018 Apr;22(6):523-534
pubmed: 26396145
Qual Life Res. 2000 Mar;9(2):185-93
pubmed: 10983482
Front Public Health. 2023 Feb 23;11:1065938
pubmed: 36908429
Int J Environ Res Public Health. 2021 Feb 21;18(4):
pubmed: 33669970
BMC Psychiatry. 2021 May 5;21(1):237
pubmed: 33952229
J Affect Disord. 2020 Dec 1;277:55-64
pubmed: 32799105
Sci Rep. 2019 Apr 4;9(1):5639
pubmed: 30948735
J Affect Disord. 2021 Feb 15;281:91-98
pubmed: 33310451
PLoS One. 2023 Mar 16;18(3):e0283227
pubmed: 36928863
Acta Psychiatr Scand. 2023 Feb;147(2):145-154
pubmed: 36464800
JAMA Psychiatry. 2023 Apr 1;80(4):331-341
pubmed: 36790774
Front Psychiatry. 2022 Nov 09;13:1008290
pubmed: 36440405
Eur Arch Psychiatry Clin Neurosci. 2022 Mar;272(2):235-255
pubmed: 33615398
J Eval Clin Pract. 2012 Apr;18(2):502-7
pubmed: 21223457
J Clin Child Adolesc Psychol. 2009 Jan;38(1):132-43
pubmed: 19130363
BMJ Med. 2022 Jun 17;1(1):e000093
pubmed: 36936553
JAMA Psychiatry. 2022 May 1;79(5):475-485
pubmed: 35293958
J Atten Disord. 2018 Mar;22(5):486-496
pubmed: 27590436
Psychiatr Prax. 2023 Jan;50(1):36-42
pubmed: 35287241
ACP J Club. 2003 Sep-Oct;139(2):48
pubmed: 12954040
J Psychiatr Res. 2021 Apr;136:190-197
pubmed: 33610946
PLoS One. 2021 Mar 25;16(3):e0249237
pubmed: 33765076
Atten Defic Hyperact Disord. 2017 Mar;9(1):47-65
pubmed: 27866355
Psychiatry (Edgmont). 2007 Jul;4(7):28-37
pubmed: 20526405
Res Social Adm Pharm. 2022 Dec;18(12):4017-4027
pubmed: 35985977
Lancet Psychiatry. 2020 Nov;7(11):955-970
pubmed: 33069318
Front Psychiatry. 2022 Apr 06;13:852664
pubmed: 35463503
Front Behav Neurosci. 2022 Jul 06;16:900981
pubmed: 35874653
World Psychiatry. 2021 Feb;20(1):124-130
pubmed: 33026219
Lancet. 2016 Mar 19;387(10024):1240-50
pubmed: 26386541
Psychol Rep. 2001 Jun;88(3 Pt 2):1075-6
pubmed: 11597055
J Psychiatr Res. 2022 Dec;156:668-678
pubmed: 36399859
BMC Psychiatry. 2020 Aug 12;20(1):404
pubmed: 32787804
J Med Internet Res. 2021 Jan 20;23(1):e22619
pubmed: 33326409
J Atten Disord. 2020 Jan;24(1):3-9
pubmed: 31257978
Br J Psychiatry. 2009 Mar;194(3):204-11
pubmed: 19252145
Psychol Med. 1990 Nov;20(4):873-9
pubmed: 2284395
Front Public Health. 2021 Nov 05;9:679041
pubmed: 34805060
Front Psychiatry. 2022 Dec 01;13:971896
pubmed: 36532188
Borderline Personal Disord Emot Dysregul. 2021 Feb 12;8(1):6
pubmed: 33579385
Eur Neuropsychopharmacol. 2016 Nov;26(11):1760-1767
pubmed: 27667705
Int J Environ Res Public Health. 2022 Sep 04;19(17):
pubmed: 36078805
PLoS One. 2016 Nov 21;11(11):e0165119
pubmed: 27870862
Psychol Psychother. 2021 Sep;94(3):854-883
pubmed: 33620133
Soc Psychiatry Psychiatr Epidemiol. 1999 Jul;34(7):360-6
pubmed: 10477956
AIMS Public Health. 2021 Aug 23;8(4):581-597
pubmed: 34786421
J Am Acad Child Adolesc Psychiatry. 2000 Sep;39(9):1135-43
pubmed: 10986810
Psychiatry Res. 2021 May;299:113848
pubmed: 33725578
Am J Psychiatry. 2006 Apr;163(4):716-23
pubmed: 16585449
J Atten Disord. 2023 Jun;27(8):830-846
pubmed: 36915033
Front Psychiatry. 2021 Mar 19;12:649399
pubmed: 33815178
J Child Psychol Psychiatry. 2022 Apr;63(4):484-496
pubmed: 34231220
Int J Environ Res Public Health. 2023 Jan 31;20(3):
pubmed: 36767967